BioRestorative Therapies

BioRestorative Therapies Receives FDA Clearance to Initiate Phase 2 Clinical Trial for the Treatment of Patients with Degenerative Disc Disease

MELVILLE, N.Y., February 8, 2017 – BioRestorative Therapies, Inc. ("BRT" or the “Company") (BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has received clearance by the U.S. Food and Drug Administration (FDA) to commence a Phase 2 clinical trial using its lead cell therapy candidate, BRTX-100, to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs.

BioRestorative Therapies Submits IND Application to FDA to Treat Patients with Degenerative Disc Disease

MELVILLE, N.Y., January 9, 2017 – BioRestorative Therapies, Inc. ("BRT" or the “Company") (BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to seek clearance to commence a clinical trial using its lead cell therapy candidate, BRTX-100, to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs.

BioRestorative Therapies Announces Presentation at 3rd Annual Regenerative Medicine Essentials Course

MELVILLE, N.Y., July 13, 2016 (GLOBE NEWSWIRE) – BioRestorative Therapies, Inc. ("BRT" or the “Company") (BRTX), a life sciences company focused on stem cell-based therapies, today announced that Ed Field, the Company’s President of the Disc/Spine Division, is presenting at the 3rd Annual Regenerative Medicine Essentials Course, held by the Wake Forest Institute for Regenerative Medicine in Winston Salem, NC. On Friday, July 15th, Mr.

BioRestorative Therapies to Present at 5th Annual Marcum MicroCap Conference

MELVILLE, N.Y., May 31, 2016 (GLOBE NEWSWIRE) – BioRestorative Therapies, Inc. ("BRT" or the “Company") (BRTX), a life sciences company focused on stem cell-based therapies, today announced that Mark Weinreb, the Company’s CEO, will present a Company overview at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016 in New York City at the Grand Hyatt Hotel. The Company’s presentation is scheduled to begin between 10:30 AM - 11:00 AM ET.

BioRestorative Therapies Deepens Board of Directors with Addition of Robert B. Catell, Former Chairman and CEO of KeySpan Corporation and Chairman of National Grid, US

Highly-Respected Business Veteran Brings Unrivaled Experience

MELVILLE, N.Y., February 23, 2016 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BRT" or the “Company") (BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has deepened its Board of Directors with the appointment of Robert B. Catell.

BioRestorative Therapies Names Lead Cell-Based Lumbar Disc Therapeutic Product

MELVILLE, N.Y., February 9, 2016 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BRT" or the “Company") (BRTX), a life sciences company focused on stem cell-based therapies, today announced that it is implementing a numeric naming for its lead cell-based therapeutic product in its disc/spine program to create a unique identity and to differentiate it from any future product formulations. Effective immediately, BRT’s lead cell therapy candidate for treating protruding and bulging lumbar disc disease will be referred to as “BRTX-100.”

Pages

Subscribe to RSS - BioRestorative Therapies
BioRestorative Therapies: A Stem Cell Biotechnology Company